SCHD, HD, LOW, UNH, REXR — Why Each Pick Plays a Different Role
SCHD, HD, LOW, UNH, REXR — Why Each Pick Plays a Different Role
TL;DR Splitting $5/day equally across SCHD, HD, LOW, UNH, and REXR isn't five copies of the same bet. Each pick passes the three-filter test (current yield, dividend growth, price appreciation) with a different score profile, and that intentional imbalance is what blends to a 12.17% growth rate — the single number that turns $5/day into $5,000/month over 30 years.
Equal dollars, different jobs
The most interesting design choice in this portfolio isn't that each stock gets the same dollar allocation. It's that each one is doing a different job with that dollar.
The trap most beginners walk into when building a dividend portfolio is grouping the highest-yield names, or alternatively, the highest-growth names. That's just five copies of the same hand. One sector hits trouble and all five wobble at once.
This portfolio's five names deliberately pass the three filters — current yield, dividend growth, and price appreciation — at different ratios. One leans current cash. One leans deferred growth. One leans diversification. Five different colors in your hand, so a single bad sector doesn't take the whole thing down.
All five at a glance
| Stock | Role | Yield | Dividend Growth | Price Appreciation |
|---|---|---|---|---|
| SCHD | Diversification anchor | 3.44% | 10.43% | 8.59% |
| HD | Consistency | 2.83% | 8.46% | 9.35% |
| LOW | 30-year payoff | 2.03% | 15.61% | 11.57% |
| UNH | Healthcare exposure | 3.27% | 12.07% | 7.78% |
| REXR | Immediate income | 5.32% | 14.28% | 6.20% |
| Blend | — | 3.38% | 12.17% | 8.70% |
That table is the whole thesis. Nobody is first place across all three filters. There are five first-place finishers, each in a different category.
SCHD — the safety net when one name breaks
Schwab US Dividend Equity ETF is the only ETF in the portfolio. That's not an accident.
SCHD holds over 100 dividend-paying companies across tech, healthcare, finance, energy, and consumer goods. If any single name in the portfolio has a brutal year, SCHD is the reason the whole thing doesn't collapse.
Across the three filters, SCHD is above average everywhere: 3.44% yield, 10.43% dividend growth, 8.59% price appreciation. Never first place anywhere, never last place either. That's exactly what an anchor should look like.
HD — the weight of 16 consecutive dividend hikes
Home Depot is the most boring pick on the list. Not the highest yield, not the fastest growth. 2.83% yield, 8.46% dividend growth, 9.35% price appreciation. Nothing flashy.
What HD does have is 16 consecutive years of dividend increases. On a 30-year timeline, consistency is more valuable than flash. A 16-year streak isn't an accident — it's a corporate signal that capital policy doesn't get yanked around when management changes.
This is the pick you don't have to second-guess. The pick that quietly raises its dividend in years when the other four are struggling. That's HD.
LOW — the slow-burning fuse
Lowe's is the opposite story. The lowest yield in the portfolio at 2.03%. The cash output in year one is almost invisible — $10,000 invested generates maybe $200 of dividends.
But LOW has the highest dividend growth rate at 15.61% and the highest price appreciation at 11.57%. First place in two of three filters.
A 15.61% growth rate doubles the dividend roughly every 4.5 years. Thirty years is nearly seven doublings. The same $200 in year one becomes ~$13,000 in year 30 if the growth rate holds.
LOW is the most frustrating name to own in year one and the most rewarding to own in year thirty. It pays patience.
UNH — the only healthcare bet in the room
The other four are tied to retail (HD, LOW, partially SCHD) or real estate (REXR). UnitedHealth breaks that concentration.
The largest health insurer in the United States. 3.27% yield, 12.07% dividend growth, 7.78% price appreciation. Not first place anywhere — but above average everywhere, in a sector none of the others touch.
The reason for UNH is straightforward. Healthcare is one of the few sectors where spending accelerates as a population ages. A 30-year simulation that ignores demographic tailwinds leaves a slot empty. UNH fills that slot.
REXR — the pick you actually feel in year one
Rexford Industrial Realty makes the trade-off explicit.
5.32% yield — first place. 14.28% dividend growth — second place. Dominant on two filters. But price appreciation is 6.2% — last place. REXR generates the most cash and grows that cash the fastest, but the share price climbs slowest.
The reason this trade-off is acceptable is psychological. In year one, the other four feel invisible. LOW pays $200, SCHD ~$350, HD ~$280, UNH ~$320. Combined, that's barely $100/month. A reasonable person quits at year two because nothing seems to be happening.
REXR breaks that pattern. The 5.32% yield delivers a meaningful number to your account from quarter one. The biggest cause of dropout in 30-year simulations isn't math — it's the feeling that "nothing is moving." REXR neutralizes that feeling.
What the blend buys you
Equal-weighted across all five, the average becomes:
- Yield: 3.38%
- Dividend growth: 12.17%
- Price appreciation: 8.7%
That 12.17% dividend growth rate is the single number that turns $5/day into $5,000/month over 30 years. SCHD alone is 10.43%. HD alone is 8.46%. Combining the five pulls the blend to 12.17%, which is why the combination outperforms any individual pick over a long horizon.
My take
I'm not arguing that copying these five names is the right move today. This is a snapshot built on the prices and fundamentals at the time the video was made. A year from now, REXR might be replaced by a different industrial REIT, and UNH by a different insurer or pharma name.
The actual lesson is the role-allocation thinking. When you're building a five-stock dividend portfolio, you should be able to write down — on paper — what job each name does. Anchor, consistency, deferred growth, sector diversifier, immediate cash. Once you can fill those five slots with your own picks, the system survives substitutions.
More in this Category
How to Bet on AI Without Single-Stock Risk — SMH, DTCR, and Three Names
How to Bet on AI Without Single-Stock Risk — SMH, DTCR, and Three Names
How to get AI infrastructure exposure without single-stock risk — SMH (+27% YTD), DTCR (+30% YTD), and three individual names (APLD, IREN, NBIS) broken down one ticker at a time.
Beats Aren't Enough — The Week Guidance Beat EPS
Beats Aren't Enough — The Week Guidance Beat EPS
Texas Instruments rallied 10% this week. IBM and ServiceNow dropped double digits. All three met or beat consensus. Here's why the outcomes split — and the framework I'm taking into next week's mega-cap prints.
SMH Just Printed 17 Up Days in a Row — Chase or Wait for the Pullback?
SMH Just Printed 17 Up Days in a Row — Chase or Wait for the Pullback?
SMH has now closed up 17 sessions in a row — possibly its longest streak ever. Intel +22%, AMD +12.6%, Nvidia +2.75% in a single day. My read: don't fight it, but don't chase it here. Wait for the pullback.
Next Posts
Four Mega-Caps in 48 Hours: The Hinge Week for 2026
Four Mega-Caps in 48 Hours: The Hinge Week for 2026
Over 20% of the S&P 500 reports next week, and Microsoft, Meta, Amazon, and Apple are clustered into a single 48-hour window. Here's why this is the hinge week for 2026 — and what to listen for in each print.
How to Bet on AI Without Single-Stock Risk — SMH, DTCR, and Three Names
How to Bet on AI Without Single-Stock Risk — SMH, DTCR, and Three Names
How to get AI infrastructure exposure without single-stock risk — SMH (+27% YTD), DTCR (+30% YTD), and three individual names (APLD, IREN, NBIS) broken down one ticker at a time.
Beats Aren't Enough — The Week Guidance Beat EPS
Beats Aren't Enough — The Week Guidance Beat EPS
Texas Instruments rallied 10% this week. IBM and ServiceNow dropped double digits. All three met or beat consensus. Here's why the outcomes split — and the framework I'm taking into next week's mega-cap prints.
Previous Posts
Palantir at 84x Sales: The Price of Perfection
Palantir at 84x Sales: The Price of Perfection
Palantir trades at 84 times revenue, and even my optimistic 10-year DCF lands the midpoint fair value at $120 — below today's $150. A great business at the wrong price is still a bad investment.
Palantir AIP vs Microsoft, Google, Amazon: Who Actually Wins Enterprise AI?
Palantir AIP vs Microsoft, Google, Amazon: Who Actually Wins Enterprise AI?
Palantir's AIP boot camps are clever, but Microsoft, Google, and Amazon already sit inside customers' daily workflows. Here's how the moats stack up across government, commercial, and pricing — and where Palantir genuinely wins versus where it gets squeezed.
The Hidden Cost of Palantir's Stock Compensation: 5 Things Long-Term Holders Miss
The Hidden Cost of Palantir's Stock Compensation: 5 Things Long-Term Holders Miss
Palantir's stock-based compensation has run above 20% of revenue — roughly 3x what mature Big Tech pays. Here are 5 things long-term holders need to understand about how dilution silently erodes per-share returns even when headline numbers look great.